Article Text

Download PDFPDF
Original article
HPV vaccination of gay, bisexual and other men who have sex with men in sexual health and HIV clinics in England: vaccination uptake and attendances during the pilot phase
  1. Marta Checchi1,
  2. David Mesher1,
  3. Mark McCall1,
  4. Flavien Coukan1,
  5. Cuong Chau1,
  6. Hamish Mohammed1,
  7. Stephen Duffell1,
  8. Michael Edelstein2,
  9. Joanne Yarwood2,
  10. Kate Soldan1
  1. 1 Blood Safety, Hepatitis, Sexually Transmitted Infections (STI) and HIV Service, Public Health England, London, UK
  2. 2 Immunisation and Countermeasures Division, Public Health England, London, UK
  1. Correspondence to Marta Checchi, Blood Safety, Hepatitis, Sexually Transmitted Infections (STI) and HIV Service, Public Health England, London SE1 8UG, UK; marta.checchi{at}


Background Human papillomavirus (HPV) vaccination for gay, bisexual and other men who have sex with men (GBMSM) aged up to 45 years attending sexual health clinics (SHC) and HIV clinics began in England as a pilot in June 2016, with national roll-out from April 2018. The recommended course is three doses of the quadrivalent HPV vaccine over one to 2 years. We present the methodology and results of monitoring vaccination uptake (initiation and completion), and attendance patterns, during the pilot phase.

Methods Total numbers of eligible GBMSM receiving HPV vaccine doses were extracted from routine datasets from pilot start to end of March 2018. Numbers of attendances since January 2009 were extracted and tested for trends before and after introduction of HPV vaccination.

Results Overall, first dose uptake was 49.1 % (23 619/48 095), with clinics with highest data completeness achieving close to 90% uptake during the pilot period. Refusals were very low (3.5%). There was no evidence of increases in the number of GBMSM attendances at pilot SHC.

Conclusions HPV vaccination has not caused important deviations to expected attendance patterns of GBMSM at SHC throughout the pilot phase. Overall, recorded initiation has been encouraging given known issues with data recording, as is current status of second and third dose completion. Attendances, vaccination initiation and completion will continue to be monitored alongside surveillance of anogenital warts diagnoses and of rectal HPV prevalence.

  • human papillomavirus
  • men who have sex with men
  • vaccination
  • evaluation
  • sexual health
  • surveillance

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Handling editor Jackie A Cassell

  • Contributors This work was initiated and designed by MC, DM, KS, JY and ME. CC, MM, HM and SD were responsible for the data collection and management. MC, DM and FC conducted the statistical analysis. MC wrote the first draft of the manuscript. All authors contributed to and approved the final version of the manuscript.

  • Funding This work was supported by Public Health England (PHE).

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Data may be obtained from a third party and are not publicly available.